Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic
Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel ant...
Gespeichert in:
Veröffentlicht in: | BMC research notes 2016-07, Vol.9 (1), p.337-337, Article 337 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 337 |
---|---|
container_issue | 1 |
container_start_page | 337 |
container_title | BMC research notes |
container_volume | 9 |
creator | Cheung Lam, Annie H Sandoval, Natalie Wadhwa, Ritambhara Gilkes, Janine Do, Thai Q Ernst, William Chiang, Su-Ming Kosina, Suzanne Howard Xu, H Fujii, Gary Porter, Edith |
description | Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.
Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed.
Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h.
Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents. |
doi_str_mv | 10.1186/s13104-016-2138-8 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4938966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468885761</galeid><sourcerecordid>A468885761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</originalsourceid><addsrcrecordid>eNptkk-LFDEQxRtR3HX1A3iRgBc99JqadCfpizAs_llY2It6DemkMhtJd8aunsH59qadddkByaFC5VePeuFV1WvglwBafiAQwJuag6xXIHStn1TnoFpZ85bzp4_uZ9ULop-cS9AanldnKyU6aPjqvIprIiQacJxZDixMiCzYeT4w66InZkfP3F1OSDNOh8T-VmIeU9zjhJ7FkaW4zZQHLDSxMe8xMZcs0SJoxzn2Mc_RvayeBZsIX93Xi-r750_frr7WN7dfrq_WN7VroNV1jysrXIdeWOXa3jWyUyEIwYWySnKnLCJ4dKoP4EPrReOhEdBa37atlr24qD4edbe7fkDvirPJJrOd4mCng8k2mtOXMd6ZTd6bphO6k7IIvLsXmPKvXTFshkgOU7Ij5h0Z0GWXTsmVLujbI7qxCU0cQy6KbsHNupFa61ZJKNTlf6hyPA7R5RFDLP2TgfcnA4WZ8fe8sTsic33745SFI-umTDRheHAK3CwpMceUmJISs6TELGu_efxFDxP_YiH-AJz4uP8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1803797628</pqid></control><display><type>article</type><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</creator><creatorcontrib>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</creatorcontrib><description>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.
Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed.
Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h.
Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</description><identifier>ISSN: 1756-0500</identifier><identifier>EISSN: 1756-0500</identifier><identifier>DOI: 10.1186/s13104-016-2138-8</identifier><identifier>PMID: 27391402</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Care and treatment ; Cholesterol Esters - pharmacology ; Cross Infection - drug therapy ; DNA, Bacterial - analysis ; DNA, Bacterial - genetics ; Drug Combinations ; Drug Compounding ; Drug Resistance, Multiple, Bacterial ; Drug Synergism ; Enterococcus faecalis - drug effects ; Enterococcus faecalis - genetics ; Enterococcus faecalis - growth & development ; Erythrocytes - drug effects ; Esters ; Fatty acids ; Fatty Acids, Nonesterified - pharmacology ; Fluorescent Dyes ; Health aspects ; Hemolysis - drug effects ; Hep G2 Cells ; Humans ; Liposomes - chemistry ; Microbial drug resistance ; Microbial Sensitivity Tests ; Organic Chemicals ; Properties ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - genetics ; Pseudomonas aeruginosa - growth & development ; Sheep ; Staphylococcus epidermidis - drug effects ; Staphylococcus epidermidis - genetics ; Staphylococcus epidermidis - growth & development ; Vancomycin - pharmacology</subject><ispartof>BMC research notes, 2016-07, Vol.9 (1), p.337-337, Article 337</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</citedby><cites>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938966/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938966/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27391402$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung Lam, Annie H</creatorcontrib><creatorcontrib>Sandoval, Natalie</creatorcontrib><creatorcontrib>Wadhwa, Ritambhara</creatorcontrib><creatorcontrib>Gilkes, Janine</creatorcontrib><creatorcontrib>Do, Thai Q</creatorcontrib><creatorcontrib>Ernst, William</creatorcontrib><creatorcontrib>Chiang, Su-Ming</creatorcontrib><creatorcontrib>Kosina, Suzanne</creatorcontrib><creatorcontrib>Howard Xu, H</creatorcontrib><creatorcontrib>Fujii, Gary</creatorcontrib><creatorcontrib>Porter, Edith</creatorcontrib><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><title>BMC research notes</title><addtitle>BMC Res Notes</addtitle><description>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.
Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed.
Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h.
Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Care and treatment</subject><subject>Cholesterol Esters - pharmacology</subject><subject>Cross Infection - drug therapy</subject><subject>DNA, Bacterial - analysis</subject><subject>DNA, Bacterial - genetics</subject><subject>Drug Combinations</subject><subject>Drug Compounding</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug Synergism</subject><subject>Enterococcus faecalis - drug effects</subject><subject>Enterococcus faecalis - genetics</subject><subject>Enterococcus faecalis - growth & development</subject><subject>Erythrocytes - drug effects</subject><subject>Esters</subject><subject>Fatty acids</subject><subject>Fatty Acids, Nonesterified - pharmacology</subject><subject>Fluorescent Dyes</subject><subject>Health aspects</subject><subject>Hemolysis - drug effects</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Liposomes - chemistry</subject><subject>Microbial drug resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Organic Chemicals</subject><subject>Properties</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - genetics</subject><subject>Pseudomonas aeruginosa - growth & development</subject><subject>Sheep</subject><subject>Staphylococcus epidermidis - drug effects</subject><subject>Staphylococcus epidermidis - genetics</subject><subject>Staphylococcus epidermidis - growth & development</subject><subject>Vancomycin - pharmacology</subject><issn>1756-0500</issn><issn>1756-0500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkk-LFDEQxRtR3HX1A3iRgBc99JqadCfpizAs_llY2It6DemkMhtJd8aunsH59qadddkByaFC5VePeuFV1WvglwBafiAQwJuag6xXIHStn1TnoFpZ85bzp4_uZ9ULop-cS9AanldnKyU6aPjqvIprIiQacJxZDixMiCzYeT4w66InZkfP3F1OSDNOh8T-VmIeU9zjhJ7FkaW4zZQHLDSxMe8xMZcs0SJoxzn2Mc_RvayeBZsIX93Xi-r750_frr7WN7dfrq_WN7VroNV1jysrXIdeWOXa3jWyUyEIwYWySnKnLCJ4dKoP4EPrReOhEdBa37atlr24qD4edbe7fkDvirPJJrOd4mCng8k2mtOXMd6ZTd6bphO6k7IIvLsXmPKvXTFshkgOU7Ij5h0Z0GWXTsmVLujbI7qxCU0cQy6KbsHNupFa61ZJKNTlf6hyPA7R5RFDLP2TgfcnA4WZ8fe8sTsic33745SFI-umTDRheHAK3CwpMceUmJISs6TELGu_efxFDxP_YiH-AJz4uP8</recordid><startdate>20160708</startdate><enddate>20160708</enddate><creator>Cheung Lam, Annie H</creator><creator>Sandoval, Natalie</creator><creator>Wadhwa, Ritambhara</creator><creator>Gilkes, Janine</creator><creator>Do, Thai Q</creator><creator>Ernst, William</creator><creator>Chiang, Su-Ming</creator><creator>Kosina, Suzanne</creator><creator>Howard Xu, H</creator><creator>Fujii, Gary</creator><creator>Porter, Edith</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160708</creationdate><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><author>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Care and treatment</topic><topic>Cholesterol Esters - pharmacology</topic><topic>Cross Infection - drug therapy</topic><topic>DNA, Bacterial - analysis</topic><topic>DNA, Bacterial - genetics</topic><topic>Drug Combinations</topic><topic>Drug Compounding</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug Synergism</topic><topic>Enterococcus faecalis - drug effects</topic><topic>Enterococcus faecalis - genetics</topic><topic>Enterococcus faecalis - growth & development</topic><topic>Erythrocytes - drug effects</topic><topic>Esters</topic><topic>Fatty acids</topic><topic>Fatty Acids, Nonesterified - pharmacology</topic><topic>Fluorescent Dyes</topic><topic>Health aspects</topic><topic>Hemolysis - drug effects</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Liposomes - chemistry</topic><topic>Microbial drug resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Organic Chemicals</topic><topic>Properties</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - genetics</topic><topic>Pseudomonas aeruginosa - growth & development</topic><topic>Sheep</topic><topic>Staphylococcus epidermidis - drug effects</topic><topic>Staphylococcus epidermidis - genetics</topic><topic>Staphylococcus epidermidis - growth & development</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung Lam, Annie H</creatorcontrib><creatorcontrib>Sandoval, Natalie</creatorcontrib><creatorcontrib>Wadhwa, Ritambhara</creatorcontrib><creatorcontrib>Gilkes, Janine</creatorcontrib><creatorcontrib>Do, Thai Q</creatorcontrib><creatorcontrib>Ernst, William</creatorcontrib><creatorcontrib>Chiang, Su-Ming</creatorcontrib><creatorcontrib>Kosina, Suzanne</creatorcontrib><creatorcontrib>Howard Xu, H</creatorcontrib><creatorcontrib>Fujii, Gary</creatorcontrib><creatorcontrib>Porter, Edith</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC research notes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung Lam, Annie H</au><au>Sandoval, Natalie</au><au>Wadhwa, Ritambhara</au><au>Gilkes, Janine</au><au>Do, Thai Q</au><au>Ernst, William</au><au>Chiang, Su-Ming</au><au>Kosina, Suzanne</au><au>Howard Xu, H</au><au>Fujii, Gary</au><au>Porter, Edith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</atitle><jtitle>BMC research notes</jtitle><addtitle>BMC Res Notes</addtitle><date>2016-07-08</date><risdate>2016</risdate><volume>9</volume><issue>1</issue><spage>337</spage><epage>337</epage><pages>337-337</pages><artnum>337</artnum><issn>1756-0500</issn><eissn>1756-0500</eissn><abstract>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.
Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed.
Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h.
Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27391402</pmid><doi>10.1186/s13104-016-2138-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1756-0500 |
ispartof | BMC research notes, 2016-07, Vol.9 (1), p.337-337, Article 337 |
issn | 1756-0500 1756-0500 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4938966 |
source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Animals Anti-Bacterial Agents - pharmacology Antibacterial agents Care and treatment Cholesterol Esters - pharmacology Cross Infection - drug therapy DNA, Bacterial - analysis DNA, Bacterial - genetics Drug Combinations Drug Compounding Drug Resistance, Multiple, Bacterial Drug Synergism Enterococcus faecalis - drug effects Enterococcus faecalis - genetics Enterococcus faecalis - growth & development Erythrocytes - drug effects Esters Fatty acids Fatty Acids, Nonesterified - pharmacology Fluorescent Dyes Health aspects Hemolysis - drug effects Hep G2 Cells Humans Liposomes - chemistry Microbial drug resistance Microbial Sensitivity Tests Organic Chemicals Properties Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - genetics Pseudomonas aeruginosa - growth & development Sheep Staphylococcus epidermidis - drug effects Staphylococcus epidermidis - genetics Staphylococcus epidermidis - growth & development Vancomycin - pharmacology |
title | Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A47%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20free%20fatty%20acids%20and%20cholesteryl%20esters%20delivered%20in%20liposomes%20as%20novel%20class%20of%20antibiotic&rft.jtitle=BMC%20research%20notes&rft.au=Cheung%20Lam,%20Annie%20H&rft.date=2016-07-08&rft.volume=9&rft.issue=1&rft.spage=337&rft.epage=337&rft.pages=337-337&rft.artnum=337&rft.issn=1756-0500&rft.eissn=1756-0500&rft_id=info:doi/10.1186/s13104-016-2138-8&rft_dat=%3Cgale_pubme%3EA468885761%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1803797628&rft_id=info:pmid/27391402&rft_galeid=A468885761&rfr_iscdi=true |